COAG Hemab Therapeutics Holdings, In
$39.40▼ -1.20%
Healthcare
Other
After hours
$40.09▲ +1.75%
Sep 11, 7:04 PM ET
Volume 408.1K
Avg Volume (10D) 363.1K
Key Metrics & Fundamentals
Market Cap
$1.84B
P/E Ratio
–
Div Yield
–%
52W Range
23.00 - 55.42
% vs 50 MA
-14.08%
% vs 200 MA
–%
RSI-14
33.6
MACD Histogram
-1.1100
Beta (1Y vs SPY)
1.49
Free Cash Flow
-$22.66M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$26.00M
COGS
–
Operating Exp
$26.08M
Operating Income
-$26.08M
EBIT
-$26.08M
Pretax Income
-$24.05M
Net Income
-$24.15M
EPS (Diluted)
-0.80
Price & Volume History
Loading chart…
Recent News
Wedbush Adjusts Price Target on Hemab Therapeutics to $64 From $55, Keeps Outperform Rating
MT Newswires · Aug 11, 2026 3:48 PM
Hemab Therapeutics' Q2 Net Loss Narrows
MT Newswires · Aug 11, 2026 11:33 AM
Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
GlobeNewswire · Aug 11, 2026 11:00 AM
Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress
GlobeNewswire · Jul 14, 2026 11:45 AM
Sector Update: Healthcare Stocks Advance Late Afternoon
MT Newswires · Jul 13, 2026 7:34 PM
Sector Update: Healthcare Stocks Higher Monday Afternoon
MT Newswires · Jul 13, 2026 5:48 PM
Hemab Therapeutics' HMB-002 Well Suited for Type 1 Von Willebrand Disease, Wedbush Says
MT Newswires · Jul 13, 2026 2:42 PM
Wedbush Raises Price Target on Hemab Therapeutics to $55 From $42, Keeps Outperform Rating
MT Newswires · Jul 13, 2026 10:54 AM
Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress
GlobeNewswire · Jul 12, 2026 10:28 AM
Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress
GlobeNewswire · Jun 26, 2026 1:00 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See COAG's money flow as a full page
Social Sentiment
No Reddit posts found for COAG.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.